Numerous lines of evidence support the likelihood that inflammation drives the transition from obese/ metabolically healthy to obese/type 2 diabetes (T2D). Given the temporal flexibility of inflammation in obesity-associated T2D, investigators have hypothesized that a precipitous drop in diabetogenic cytokines is critical for rapid 'T2D remission' following surgery but prior to significant weight loss. We review the evidence that changes in diabetogenic cytokines play a role in outcomes of bariatric surgery, including improved glycemic control.
INTRODUCTION
Bariatric surgery, most commonly Roux-en-Y gastric bypass (RYGB), is an effective intervention for morbid obesity and obesity-associated type 2 diabetes (T2D) [1] [2] [3] . Recent recommendations indicate bariatric surgery as the preferred treatment for T2D in class III obese (BMI 40) patients, with consideration of surgery for class II obese people (BMI 35-39.9) with inadequately controlled hyperglycemia [4 && ]. Most patients show significant metabolic improvement after bariatric surgery, with T2D remission rates of up to 70% of patients 2 years after RYGB [5] and evidence for T2D remission as soon as 1 week after surgery [6] . Using longitudinal data from a large registry of bariatric patients, we developed a predictive scoring system, DiaRem, which uses readily available clinical data to provide a likelihood of remission. DiaRem integrates data showing that younger patients with lower percentage of HbA1c, who are not on insulin are disproportionately likely to remit their T2D early after surgery [7,8 && ]. Insulin therapy, older age, and high presurgery % HbA1c predicts low likelihood for T2D remission, clearly pointing to an essential role for a functioning b-cell population for diabetes remission after surgery. However, a gap remains in accuracy of DiaRem, and in comprehensive identification of mechanisms that regulate T2D remission following bariatric surgery, and in our ability to develop nonsurgical techniques that mimic the advantages of bariatric surgery-mediated T2D remission on an individualized basis.
Inflammation is a known complication of obesity that supports T2D development and differentiates metabolically healthy from metabolically unhealthy obesity [9] . Inflammatory status can change rapidly, due in part to the tight regulation of cytokine production [10,11,12 && ,13,14] , raising the possibility that a precipitous drop in diabetogenic cytokines is important for rapid postsurgical T2D remission. By extension, failure of inflammation to resolve after surgery may blunt improvements in glycemic control. A growing number of studies have measured traditional mediators of diabetogenic inflammation, including TNFa, IL-6, and CRP (C-reactive protein) at various time points following bariatric surgery (detailed below). However, differences in experimental design of these studies, coupled with recent work that refines the generic term 'inflammation' in obesity and T2D [12 && ], suggest that longitudinal analysis of inflammation, focused on dominant inflammatory signatures of T2D and standardized surgical procedures, may improve our understanding of the role inflammation plays in surgically induced T2D remission.
MECHANISMS UNDERLYING IMPROVED GLYCEMIC CONTROL FOLLOWING BARIATRIC SURGERY
The ability of RYGB to 'cure' T2D was first recognized by Pories and colleagues [2] 20 years ago. More recent studies showed up to 70-85% T2D remission [1, 15, 16] even before weight loss [6] . RYGB most effectively achieves a rapid improvement in glycemic control if T2D patients are younger, have lower HbA1c levels, and are not on insulin [17, 18] .
Progress in identifying the mechanisms underlying improvements in glycemic control following RYGB and other types of bariatric surgery prior to significant weight loss has recently accelerated. The dominant hypothesis is that physical removal of tissues in some bariatric procedures leads to early arrival of nutrients in the distal ileum and increased incretin secretion [19,20,21 && ], which together are responsible for rapid glycemic improvement in RYGB. Alternatively, recent work in rats has shown that expansion of the small intestine in response postsurgical exposure to less fully digested food requires high amounts of glucose [22] . These data support the authors' conclusion that the requirement for glucose for intestinal growth depletes circulating glucose, thus the clinical appearance of T2D remission. The moderate numbers of current studies have not assessed inflammation prior to significant weight loss, in part based on the expected inflammatory spike as a normal intrasurgical or immediately postsurgical event [23
THE IMPACT OF BARIATRIC SURGERY ON DIABETOGENIC INFLAMMATION
Although studies showing improved glycemic control within a week of bariatric surgery have not investigated potential changes in inflammation, several studies have measured classical markers of diabetogenic inflammation at various time points following different surgical procedures. The inflammatory markers most often measured in bariatric surgery outcome studies include: TNFa, the first inflammatory cytokine implicated in obesity-associated metabolic derangement [26] ; IL-6, a pleiotropic cytokine that has complex effects on obesity-associated metabolic decline [27] [28] [29] ; and CRP and serum amyloid A (SAA), two acute phase proteins that are imperfect yet commonly used indicators of inflammation [30] . Overall, the effect of surgery and/or surgically induced weight loss on inflammation has been inconsistent [31-36,37 & ].
THE EFFECT OF BARIATRIC SURGERY ON TNFa
TNFa is arguably the most frequently quantitated cytokine in serum/plasma of postsurgical patients due to strong associations of TNFa with insulin resistance [38] . TNFa concentrations at 2 weeks, 6 months, and/or 13 months after laparoscopic RYGB were indistinguishable from presurgical/baseline levels in two independent studies [35,39 & ]. A third study of samples from patients undergoing
KEY POINTS
Inflammation promotes the transition from obese and metabolically healthy to obese and metabolically unhealthy.
Measures of inflammatory changes following bariatric surgery, including TNFa, IL-6, and acute phase proteins (CRP and SAA) are inconsistent despite the demonstrated impact of surgery on weight loss and T2D remission.
Inflammatory proteins shown to predict T2D through multivariate analytical approaches have not been tested for impact on T2D remission following bariatric surgery.
Longitudinal studies, coupled with an appreciation of potential differences in inflammation due to differences in surgical techniques and sample timing, will be absolutely essential to assess the importance of inflammation in bariatric surgery outcomes, including T2D remission and T2D recurrence following transient remission.
laparoscopic RYGB showed TNFa significantly increased 3 months after surgery compared with baseline, while recapitulating the other studies' findings of no change in TNFa in comparison at 6 and 12 month after surgery [36] . In contrast, a fourth analysis of TNFa 3 weeks to 6 months after RYGB showed a significant decrease at each time point compared with baseline [31] . This latter outcome was consistent with rat RYGB work showing that adipose tissue mRNA levels of TNFa decreased 9 weeks postoperatively compared with the sham procedure, although RYGB did not alter TNFa amounts in the rats' livers [25] . Thus the impact of RYGB on TNFa remains controversial.
In contrast to the inconsistency of RYGB for inducing changes in TNFa across studies, the impact of laparoscopic adjustable gastric banding (LAGB) on TNFa is relatively consistent, with multiple groups showing no change in serum levels anywhere from 2 weeks up to 14 months postoperatively [40, 41] despite an improvement in markers of glucose homeostasis [42] , and a preoperative correlation between insulin resistance and serum TNFa [40] . Although findings for circulating TNFa following LAGB all show no change, Moschen et al. [43] found that TNFa in subcutaneous adipose tissue dramatically dropped, and that adipose tissue TNFa mRNA correlated with improved insulin sensitivity 6 months after LAGB. Interestingly gastric bandingassociated weight loss also reduced T-cell numbers [42] . Taken together, the existing studies suggest that the exact surgical procedure (RYGB vs. LAGB) may impact the postsurgical TNFa response. Perhaps most importantly, this work shows inconsistency among studies, and calls for comparisons among outcomes from a standardized set of surgical procedures to understand the impact of bariatric surgery on TNFa-associated inflammation.
THE EFFECT OF BARIATRIC SURGERY ON CIRCULATING IL-6
IL-6 is often considered a strictly proinflammatory cytokine, but IL-6 has broader biologic properties, based in part on differences in the signaling cascades activated by the subunit composition of the two recognized IL-6 receptors [44, 45] . As a result of the well known duplicity of IL-6, it is perhaps unsurprising that both gain-of-IL-6-function and lossof-IL-6-function in mice and/or humans (knockout, neutralizing antibody, or IL-6 infusion) improve glycemic control [27] [28] [29] . Regardless of the precise role of IL-6 in obesity and obesity-associated metabolic disease, many investigators have measured IL-6 following after bariatric surgery weight loss. IL-6 concentrations were unchanged in T2D patients 2 weeks after RYGB and a 7% weight loss [37 & ]. An independent measurement of IL-6 at baseline and 3, 6, and 12 months after RYGB indicated significant increases only at the 3-month time point [36] . In contrast, several studies agree that IL-6 decreases 12-14 months after RYGB [24 & ,46]; however, the studies disagreed on whether IL-6 correlated with BMI, insulin concentrations, or homeostatic model assessment of insulin resistance (HOMA-IR). Omentectomy during RYGB did not significantly affect IL-6 12 months after RYGB [47] . Similar to the lack of consistency in studies measuring IL-6 changes after RYGB, the changes in serum IL-6 levels after LAGB varied across studies: Samaras et al. [42] noted a transient decrease in IL-6 2 weeks after LAGB, which then returned to baseline at 12 weeks, despite a significant improvement in the glycemic control of T2D patients. Independent analysis similarly showed no change in IL-6 12 months after surgery and following significant weight loss [41, 43] . In contrast, a fourth study found a reduction in serum, subcutaneous adipose tissue, and liver IL-6 that correlated with improved insulin sensitivity 6 months after LAGB [43] , consistent with other work [40] . Taken together, these studies indicate that comparisons of nearly identical surgical procedures at matched time points after surgery will be essential to understand the impact of bariatric surgery on IL-6-mediated inflammation.
THE EFFECT OF BARIATRIC SURGERY ON ACUTE PHASE PROTEINS
CRP, an acute phase liver protein that rapidly rises in response to injury or inflammation, is a traditional (albeit imperfect) measure of inflammation [48] . Generally speaking, serum CRP levels drop following bariatric surgery with a decline that correlates with weight loss as indicated by studies that measured CRP 6 months after sleeve gastrectomy [49] . Detectable decreases have also been noted as early as 1 month postoperative [50] . CRP also significantly decreased 6 months after LAGB [43] , and was similarly low for 12 months in an independent (though procedurally similar) analysis following LAGB [41] . CRP concentrations have also been measured in samples from patients who received RYGB, with investigators taking measurements at various time points ranging from 6 to 52 weeks postoperative. At 12 months postoperative, patients averaged an 82% reduction in CRP, which was more pronounced in those who were insulin sensitive (as indicated by a HOMA-IR of <4) at baseline. The change in CRP associated with HOMA-IR but was independent of the change in body weight in these patients [46] . In contrast, CRP reduction did not correlate with HOMA-IR 14 months after gastroplasty, but instead independently correlated with BMI reduction [40] . Similar to the surgically induced drop in CRP in the studies cited above, a more thorough longitudinal analysis of highsensitivity CRP at 3, 6, and 12 months after RYGB showed progressive drops from baseline at all three time points, and correlated with BMI, insulin, and HOMA-IR [36] . This work recapitulates the drop in CRP measured after RYGB-induced weight loss of 7% [37 & ]. Finally, one study [51] of Korean T2D patients showed CRP decreased about the same in people with and without T2D remission following RYGB. Overall, unlike the variable changes in TNFa, IL-6, and other obesity-associated inflammatory molecules [such as monocyte chemoattractant protein-1 (MCP-1), IL-8, and so on] following various weight loss surgeries, CRP generally falls, raising the possibility that bariatric procedures lower the risk of cardiovascular disease in obese patients.
Like CRP, serum amyloid (SAA) is an acute phase reactant synthesized by the liver in response to inflammation [52] . SAA is increased in obesity [53, 54] , and obesity-associated complications, including atherosclerosis [55, 56] . Twelve months after RYGB, SAA decreased by 57% in a group of 66 obese patients. The SAA reduction paralleled lower CRP, but CRP remained more significantly correlated with BMI change than did SAA [46] . A similar study looking at the relationship between T2D and SAA before and 13 months after RYGB, in a small cohort of women with or without T2D found that RYGB significantly reduced circulating SAA, which correlated strongly with the reduction in body fat, but was independent of T2D status [35] . Work by Poitou et al. [57] further reinforced these findings by demonstrating that a mixed cohort of obese RYGB and LAGB patients had reduced serum SAA 3 months after surgery. SAA concentrations failed to correlate with metabolic markers such as glucose, insulin, and plasma lipids, but instead correlated with BMI and adipocyte volume. Importantly, serum SAA protein correlated with mRNA expression of inducible SAA (isoforms 1 and 2) from subcutaneous adipose tissue [57] . Overall, the data indicate that obesity-associated increases in SAA concentrations are related to adiposity rather than insulin resistance, and that like CRP, SAA generally falls as a result of multiple weight loss surgery procedures. Taken together, these data indicate that acute phase proteins change more predictably than TNFa, IL-6, or other cytokines measured (MCP-1, IL-8 etc.) [39 & ,58-60] following bariatric surgery (Fig. 1) . One exception to the variability in cytokine responses to bariatric surgery is adiponectin, a generally anti-inflammatory cytokine made by adipocytes, which uniformly increases after surgery [36, 61] .
CONCLUSION
The relationships among measures of postsurgical cytokines, acute phase proteins, and metabolic health improvements, including T2D remission, remain poorly understood. The widely predicted drop in T2D-promoting inflammation following bariatric surgery-induced weight loss has been inconsistently supported over numerous studies that differ in surgical procedure, postsurgical time point, and tissue studied. It is possible that fundamental differences in mechanisms that regulate inflammatory cytokines (TNFa, IL-6, IL-8, and so on) and acute phase proteins (CRP and SAA) together with the different surgical procedures explain the unpredictability of the inflammation outcomes, and may also explain the inconsistency of the relationships between both types of inflammatory markers and measures of metabolic improvement. It is equally possible that technical differences in sample collection/handling account for the varying outcomes, including the small sample number (and unreported power) used for many studies. Our preliminary work indicates that, in contrast to the recognizable cytokine signatures we found by stimulating peripheral blood mononuclear cells (PBMCs) from obese/T2D patients [12 && ], cytokine signatures in plasma or serum yields weak suggestions of relationships between obesity and measures of metabolic health, perhaps due in part to low signal-to-noise ratios. We predict a more comprehensive analytical screen on stimulated PBMCs as we published [12 && ], with cells collected before and at multiple time points after bariatric surgery, both separate and integrated analysis of the different surgical techniques, and addition of metabolic variables to the multivariate analyses to shed light on the role inflammation plays in outcomes following various types of bariatric surgery ( Table 1) . Given the ability of cytokine profiles from stimulated PBMCs to predict clinical disease status [12 && ], presurgical inflammatory profiling may also help identify people who are likely to maximally benefit from a given surgical approach, and perhaps most importantly, to predict those for whom bariatric surgery will not trigger significant weight loss or T2D remission. Finally, in light of new data showing that surgically induced T2D remission may not be permanent, especially in nonwhites [62 && ], coupled with the general paradigm that inflammation is critical for metabolic decline in obese individuals [9] , analysis of inflammatory profiles may be important for understanding permanency of metabolic improvement after surgery. Determining relationships among inflammatory mediators, pancreatic b-cell function and T2D remission will be absolutely essential toward shifting the standard of care to maximally benefit patients. 
